Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Phase 1/2 Recruiting 20 enrolled University of Miami

NaSingle-groupOpen-labelTreatment

Summary

This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients \< 22 years of age.

Timeline

Start: 2025-06-19
Primary completion: 2029-10-01
Completion: 2029-12-01

Publications

Background McCrea HJ, Ivanidze J, O'Connor A, Hersh EH, Boockvar JA, Gobin YP, Knopman J, Greenfield JP. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial. J Neurosurg Pediatr. 2021 Aug 6;28(4):371-379. doi: 10.3171/2021.3.PEDS20738. Print 2021 Oct 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	Other
Subject	Cetuximab	Monoclonal antibody	200 mg/m2	Other

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Summary

Timeline

Publications

Drugs

Indications